Literature DB >> 23033928

Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma.

Shen-Nien Wang1, King-Teh Lee, Chia-Jung Tsai, Yu-Jie Chen, Yao-Tsung Yeh.   

Abstract

BACKGROUND: The p38 and JNK MAPK proteins function as key mediators in cellular responses to extracellular stimuli. Deregulated p38 and JNK expressions have been associated with cancer development. This study aimed to investigate the association of p-p38 and p-JNK levels of the cancerous tissues with hepatocellular carcinoma (HCC) development.
MATERIALS AND METHODS: One hundred and four liver cancer tissues of patients with HCC who underwent curative resection were prospectively collected. The levels of activated/p-p38 and p-JNK were determined by the enzyme-linked immunosorbent assay. The associations of results with clinicopathological characteristics and overall survival were further statically analysed using chi-squared test, two-tailed Student's t-test and Kaplan-Meier survival curve.
RESULTS: The p-p38 levels were significantly higher in the HCC patients with a larger tumour (≥ 3 cm) and satellite tumour, and significantly correlated with the p-JNK levels. High p-p38 and low p-JNK expressions were associated with a poor survival in the patients with HCC (odds ratio, 4·24 and 0·20; P = 0·03 and 0·03, respectively). The Kaplan-Meier survival analysis showed that the HCC patients with high p-p38 expressions had a poor overall survival than those with low p-p38 expressions (P = 0·04), and a coexistent and high p-JNK expression remarkably improved this trend.
CONCLUSIONS: Increasing p-p38 levels in HCC tissues were associated with tumour size and the formation of satellite tumours. High p-p38 expression could serve as a predictor for a poor survival for the patients with HCC. Simultaneous expression of p-JNK in HCC tissues might antagonize the promoting effect of p-p38 in human liver cancer.
© 2012 The Authors. European Journal of Clinical Investigation © 2012 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23033928     DOI: 10.1111/eci.12003

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  23 in total

1.  Hepatitis B virus X protein promotes DNA damage propagation through disruption of liver polyploidization and enhances hepatocellular carcinoma initiation.

Authors:  James Ahodantin; Myriam Bou-Nader; Corinne Cordier; Jérôme Mégret; Patrick Soussan; Chantal Desdouets; Dina Kremsdorf
Journal:  Oncogene       Date:  2018-12-11       Impact factor: 9.867

Review 2.  p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.

Authors:  Valentina Grossi; Alessia Peserico; Tugsan Tezil; Cristiano Simone
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Proline isomerisation as a novel regulatory mechanism for p38MAPK activation and functions.

Authors:  A Brichkina; N Tm Nguyen; R Baskar; S Wee; J Gunaratne; R C Robinson; D V Bulavin
Journal:  Cell Death Differ       Date:  2016-05-27       Impact factor: 15.828

4.  p38α MAPK is required for arsenic-induced cell transformation.

Authors:  Hong-Gyum Kim; Chengcheng Shi; Ann M Bode; Zigang Dong
Journal:  Mol Carcinog       Date:  2015-05-12       Impact factor: 4.784

Review 5.  Molecularly targeted therapies for p53-mutant cancers.

Authors:  Dekuang Zhao; William M Tahaney; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Cell Mol Life Sci       Date:  2017-06-22       Impact factor: 9.261

Review 6.  Twist in hepatocellular carcinoma: pathophysiology and therapeutics.

Authors:  Hui Zou; Xing Feng; Jian-Guo Cao
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

7.  The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.

Authors:  Khanh Vinh Quốc Lu'o'ng; Lan Thi Hoàng Nguyễn
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989

8.  Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.

Authors:  Lirui Zhang; Xiaofeng Yang; Xu Li; Chen Li; Le Zhao; Yuanyuan Zhou; Huilian Hou
Journal:  Int J Mol Med       Date:  2015-08-24       Impact factor: 4.101

9.  Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK.

Authors:  Lorena Pereira; Ana Igea; Begoña Canovas; Ignacio Dolado; Angel R Nebreda
Journal:  EMBO Mol Med       Date:  2013-09-24       Impact factor: 12.137

10.  Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma.

Authors:  Wei-Hua Xu; Jian-Bin Zhang; Zheng Dang; Xiao Li; Ti Zhou; Jie Liu; De-Sheng Wang; Wen-Jie Song; Ke-Feng Dou
Journal:  Int J Biol Sci       Date:  2014-06-10       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.